
BIOGF
Healthcare · Diagnostics & Research · $65.4M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.34 | — |
| Sep 2, 2020 | After the close | 0.00 | -0.33 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.31 | — |
| Mar 4, 2020 | After the close | 0.00 | -0.31 | — |
| Nov 13, 2019 | After the close | 0.00 | -0.34 | — |
| Sep 4, 2019 | After the close | 0.00 | -0.33 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | -0.30 | — |
| Feb 28, 2019 | After the close | 0.00 | -0.30 | — |
| Nov 15, 2018 | Before the open | 0.00 | -0.30 | — |
| Sep 5, 2018 | After the close | 0.00 | -0.30 | — |
| Apr 25, 2018 | After the close | 0.00 | -0.25 | — |
| Feb 28, 2018 | After the close | 0.00 | -0.26 | — |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The…